Вимпат® (Лакосамид)
Проводит ЮСБ Биосайенсез Инк.
Страница компанииМногоцентровое, двойное слепое, рандомизированное, плацебо-контролируемое исследование в параллельных группах для изучения эффективности и безопасности лакосамида в качестве дополнительной терапии у пациентов c эпилепсией с парциальными приступами в возрасте от ≥ 1 месяца до < 4 лет
Постоянная ссылка: https://clinomir.ru/trials/permit/ru/94/2019-02-28/
Источник: ГРЛС — Государственный реестр лекарственных средств Минздрава России; ClinicalTrials.gov (U.S. National Library of Medicine); clinmarket. Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 1 мес. — 3.9 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 55 чел. в стране «Россия».
- Центров в реестре: 13 в 11 городах. Список — ниже на странице.
- Плановая дата окончания (06.2020) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 8 · невключение: 13
Критерии включения
- Subject is male or female from >=1 month (ie, 4 weeks after full term \[37 weeks gestational age\]) to <4 years of age
- Subject has a diagnosis of epilepsy with partial-onset seizures. The results of >=1 prior EEG and >=1 magnetic resonance imaging/computerized tomography scan should be consistent with this diagnosis
- Subject weighs >=4 kg to <30 kg at Visit 1
- Subject has experienced >=2 partial-onset seizures with or without secondary generalization during each consecutive 7-day period during the 2 weeks prior to Visit 1
- Subject has >=2 partial-onset seizures with or without secondary generalization during the End-of-Baseline video-EEG. Electrographic seizures are defined as recognizable ictal patterns on an EEG involving >=2 contiguous electrodes. The seizures are initiated as a unilateral or strongly asymmetric abnormal epileptiform discharge lasting a total of >10 seconds
- Subject is on a stable (concurrently or sequentially) dosage regimen of 1 to 3 AEDs. The dosage regimen of concomitant AED therapy must be kept constant for a period of >=2 weeks prior to Visit 1. A stable daily dosage regimen of a concomitant benzodiazepine (BZD) will be considered as a concomitant AED
- Vagus nerve stimulation (VNS) is allowed and will not be counted as a concomitant AED. The VNS device must have been implanted for >=6 months prior to Visit 1; device settings must be kept stable for >=2 weeks prior to Visit 1 and kept stable during the Baseline, Treatment, and Transition Periods. Use of the VNS device magnet is allowed
- Subject is an acceptable candidate for venipuncture
Критерии невключения
- Subject has experienced febrile seizures exclusively. The occurrence of febrile seizures in addition to partial-onset seizures is not exclusionary
- Subject is on a ketogenic diet that has either changed within the 4 weeks prior to Visit 1 or is expected to change during the study
- Subject has creatinine clearance <30 mL/minute
- Subject has a clinically relevant ECG abnormality, in the opinion of the investigator (eg, second or third degree heart block at rest or a corrected QT interval \[QTc\] >=450 ms)
- Subject has a hemodynamically significant congenital heart disease
- Subject has an arrhythmic heart condition requiring medical therapy
- Subject has a known history of severe anaphylactic reaction secondary to medication intake or serious blood dyscrasias
- Subject has nonepileptic events that could be confused with seizures. Subjects may be included if epileptic events can be clearly distinguished and the frequency meets the study inclusion criteria
- Subject has a current diagnosis of Lennox-Gastaut syndrome, epilepsia partialis continua, primary generalized epilepsy, Dravet Syndrome, or seizures that are not of partial-onset origin
- Subject has a history of generalized convulsive status epilepticus <=2 months prior to Screening (Visit 1)
- Subject has been treated with felbamate and has experienced any serious toxicity issues (defined as liver failure, aplastic anemia) with this treatment. Subjects treated with felbamate for <12 months are excluded. Subjects treated with felbamate for >=12 months prior to Visit 1 and who have not experienced serious toxicity issues are eligible
- Subject has an acute or subacutely progressive central nervous system disease. Subject has epilepsy secondary to a progressing cerebral disease or any other progressively neurodegenerative disease (malignant brain tumor or Rasmussen Syndrome)
- Subject has a known cardiac sodium channelopathy, such as Brugada syndrome
Источник: ClinicalTrials.gov, NCT02477839 · запись обновлена в реестре 1 июля 2021.
Дизайн и результаты
Что измеряют — первичные конечные точки (3), вторичных — 9
- Change in Average Daily Frequency (ADF) of Electrographic Partial-onset Seizures From End-of-Baseline (EOB) Period Video-EEG to End-of-Maintenance (EOM) Period Video-EEG — End-of-Baseline Period (Day -3 to Day 1) to End-of-Maintenance Period (Day 24 to Day 27)
- Participant Withdrawals Due to Adverse Events (AEs) During the Study — From the Baseline Period (Day -7) to the End of Study Visit (up to 93 days)
- Percentage of Participants With Adverse Events Reported Spontaneously by the Participant's Parent(s) and/or Legal Representative(s)/Caregiver(s) (in Accordance With Local Regulation) or Observed by the Investigator — From the Baseline Period (Day -7) to the End of Study Visit (up to 93 days)
Цель исследования
The purpose of this trial is to assess the efficacy, safety and tolerability of lacosamide administered as add-on therapy with 1 to 3 anti-seizure medications. This trial is for children aged 1 month to less than 4 years with epilepsy who currently have uncontrolled partial-onset seizures.
Области и заболевания
Где проходит
13 центров в 11 городахОткуда эта информация
-
ГРЛС — Государственный реестр лекарственных средств Минздрава России · № 94 от 28.02.2019 Официальный реестр · загружено 1 октября 2026Препарат, номер протокола, название, разрешение, фаза, сроки, число участников, спонсор, разработчик
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT02477839 Официальный реестр (США) · загружено 9 ноября 2026Цель, центры
-
clinmarket · № 1254 Каталог исследований · загружено 1 октября 2026Статус
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.